Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioMérieux – First-Half 2019 Results
04 September, 2019
bioMérieux – 2018 Financial Results
27 Februar, 2019
bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing
07 Februar, 2019
bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.
bioMérieux – Business review for the nine months ended
30 September, 2018
bioMérieux – First-Half 2018 Results
05 September, 2018
bioMérieux – Second-Quarter 2018 Business Review
18 Juli, 2018
EUROPEAN DAIRY QUALITY CONFERENCE
13 März, 2018
24th May 2018Lindner Hotel & City Lounge, Lange Kievitstraat 125, Antwerp, Belgium